I.3 An epigenetic mechanism for tamoxifen-associated uterine carcinogenesis?

P. L. Carmichael*, J. J. Mills, P. Neven

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Tamoxifen is a potent anti-oestrogenic drug effective in treating human breast cancer but is associated with an increase in endometrial tumours in some women. Although tamoxifen is an oestrogen antagonist in the breast it possesses partial agonist activity in the human uterus. We hypothesise that tamoxifen's carcinogenic activity in the endometrium involves dysregulation of the transforming growth factor-beta (TGFβ) activation and signalling pathway. Consequently, we are screening human biopsies for alterations in these TGFβ pathways. Altered responsiveness to TGFβ signalling could form the basis of an epigenetic mechanism for endometrial carcinogenesis with tamoxifen.

Original languageEnglish
Pages (from-to)S10-S11
JournalEuropean Journal of Cancer
Issue numberSUPPL. 4
Publication statusPublished - Aug 1998


Dive into the research topics of 'I.3 An epigenetic mechanism for tamoxifen-associated uterine carcinogenesis?'. Together they form a unique fingerprint.

Cite this